Literature DB >> 8843738

Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig.

C F Deacon1, L Pridal, L Klarskov, M Olesen, J J Holst.   

Abstract

Glucagon-like peptide 1 (GLP-1) metabolism was studied in halothane-anesthetized pigs (n = 7) using processing-independent (PI) and COOH-terminal (C) radioimmunoassays (RIA) and an enzyme-linked immunosorbent assay (ELISA) specific for biologically active GLP-1. Renal extraction of endogenous GLP-1 was detected by PI-RIA (33.1 +/- 13.3%) and C-RIA (16.0 +/- 6.3%) and by all assays during GLP-1 infusion (ELISA, 69.4 +/- 6.3%; PI-RIA, 32.6 +/- 7.3%; C-RIA, 43.7 +/- 3.4%), indicating substantial fragmentation. Hepatic and pulmonary degradation were undetectable under basal conditions, but exogenous GLP-1 elimination by the liver (43.6 +/- 8.9%) and lungs (10.1 +/- 3.2%) was measured by ELISA, suggesting primarily NH2-terminal degradation. Endogenous GLP-1 extraction by the hindleg was only detected by C-RIA (16.0 +/- 6.3%). During GLP-1 infusion, greater hindleg extraction was measured by ELISA (38.5 +/- 6.8%) and C-RIA (33.0 +/- 6.4%) than by PI-RIA (11.4 +/- 3.2%), indicating limited degradation at each terminus or more substantial COOH-terminal degradation. A shorter (P < 0.01) plasma half-life was revealed by ELISA (1.5 +/- 0.4 min) than by PI-RIA (4.5 +/- 0.6 min) or C-RIA (4.1 +/- 0.5 min). Metabolic clearance rates measured by PI-RIA (20.0 +/- 3.8 ml.min-1.kg-1) and C-RIA (15.5 +/- 1.6 ml.min-1.kg-1) were shorter (P < 0.01) than that measured by ELISA (106.8 +/- 14.7 ml.min-1.kg-1). Tissue-specific differential metabolism of GLP-1 occurs, and NH2-terminal degradation, rendering GLP-1 inactive, is particularly important in its clearance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843738     DOI: 10.1152/ajpendo.1996.271.3.E458

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  77 in total

Review 1.  G protein-coupled receptors as targets for anti-diabetic therapeutics.

Authors:  Da Young Oh; Jerrold M Olefsky
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

3.  Degradation of Incretins and Modulation of Blood Glucose Levels by Periodontopathic Bacterial Dipeptidyl Peptidase 4.

Authors:  Yuko Ohara-Nemoto; Manami Nakasato; Yu Shimoyama; Tomomi T Baba; Takeshi Kobayakawa; Toshio Ono; Takashi Yaegashi; Shigenobu Kimura; Takayuki K Nemoto
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

Review 4.  Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling.

Authors:  Charlotte C Ronveaux; Daniel Tomé; Helen E Raybould
Journal:  J Nutr       Date:  2015-02-04       Impact factor: 4.798

5.  Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.

Authors:  J J Holst; C F Deacon
Journal:  Diabetologia       Date:  2005-03-10       Impact factor: 10.122

Review 6.  Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

Authors:  J J Holst
Journal:  Diabetologia       Date:  2006-01-14       Impact factor: 10.122

7.  Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs.

Authors:  K R Hjøllund; C F Deacon; J J Holst
Journal:  Diabetologia       Date:  2011-05-21       Impact factor: 10.122

8.  GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat.

Authors:  Lena Ohlsson; Alison B Kohan; Patrick Tso; Bo Ahrén
Journal:  Regul Pept       Date:  2014-02-28

9.  Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.

Authors:  Julio Rosenstock; Jane Reusch; Mark Bush; Fred Yang; Murray Stewart
Journal:  Diabetes Care       Date:  2009-07-10       Impact factor: 19.112

10.  Peptidase substrates via global peptide profiling.

Authors:  Debarati M Tagore; Whitney M Nolte; John M Neveu; Roberto Rangel; Liliana Guzman-Rojas; Renata Pasqualini; Wadih Arap; William S Lane; Alan Saghatelian
Journal:  Nat Chem Biol       Date:  2008-11-16       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.